CAS:135062-02-1Repaglinide

Synonyms: AG-EE623 ZW;NN-623

Repaglinide is a carbamoylmethyl benzoic acid (CMBA) derivative, which recently has become available for the treatment of type II diabetes.

规格	价格	促销价格	库存

18817579266

立即询价

咨询

18817579266

立即询价

实验数据

技术信息

CAS号

135062-02-1

储存条件

分子式

C27H36N2O4

运输

蓝冰

分子量

452.59

别名

AG-EE623 ZW;NN-623

溶解度

动物实验配方

5% DMSO+2% Tween80+30% PEG300+water

0.3 mg/mL

clear

生物活性

描述Repaglinide is an insulin secretagogue for the treatment of type-2 diabetes mellitus. Repaglinide reduces postprandial glucose levels by enhancing the early phase of insulin secretion and increasing the total amount of insulin secreted. Furthermore, Repaglinide is inactivated in the liver and more than 90% excreted via the bile. Repaglinide (1 mg/kg p.o.) is effective as an insulin-releasing agent in a rat model (low-dose streptozotocin) of type 2 diabetes^[3]. Repaglinide lowers fasting and postprandial blood glucose levels in animals, healthy volunteers and patients with type 2 diabetes mellitus. Repaglinide is rapidly absorbed and eliminated, which may allow a relatively fast onset and offset of action. Excretion occurs almost entirely by non-renal mechanisms. In comparative clinical trials in patients with type 2 diabetes mellitus, repaglinide 0.5 to 4 mg twice or 3 times daily before meals provided similar glycaemic control to glibenclamide (glyburide) 2.5 to 15 mg/day^[4]. Moreover, repaglinide significantly reduced Bcl-2, Beclin-1 and PD-L1 expression in glioma tissues, indicating that repaglinide may exert its anti-cancer effects via apoptotic, autophagic and immune checkpoint signaling^[5].